At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
pemetrexed plus cisplatindrug
Likely dose
pemetrexed plus cisplatin 500mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
In Brief
A Phase 4 clinical trial evaluating pemetrexed plus cisplatin for Locally Advanced Malignant Neoplasm. Completed, enrolled 28 participants across 1 site.
Detailed Summary
For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer. The combination of these two drug may have a synergy with each other in treatment of advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Malignant Neoplasm
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedJun 15, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2012
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 16.0 years ago
Interventions
pemetrexed plus cisplatindrug
pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression